Asthma Drugs Market Dynamics: Competitive Shifts Among Global Industry Players

The Business Research Company’s Asthma Drugs Global Market Report 2026 – Market Size, Trends, And Forecast 2026–2035

The Business Research Company’s Asthma Drugs Global Market Report 2026 – Market Size, Trends, And Forecast 2026–2035

LONDON, GREATER LONDON, UNITED KINGDOM, April 28, 2026 /EINPresswire.com/ -- The asthma drugs market is dominated by a mix of global pharmaceutical companies and specialty respiratory therapy firms. Companies are focusing on the development of advanced biologics, combination inhalers, targeted therapies, and innovative drug delivery systems to enhance treatment efficacy and patient adherence. Emphasis on regulatory approvals, clinical research, personalized medicine approaches, and expansion of product portfolios remains central to competitive positioning. Understanding the competitive landscape is essential for stakeholders seeking growth opportunities, therapeutic advancements, and strategic collaborations within the evolving respiratory care and chronic disease management sector.

Which Market Player Is Leading The Asthma Drugs Market?
•According to our research, Sanofi S.A. led global sales in 2024 with a 57% market share. The company’s strong position in the asthma drugs market is supported by its portfolio of biologics and inhalation therapies, focusing on targeted treatments for severe asthma, improved patient adherence solutions, and continuous investment in respiratory research and development to address unmet clinical needs.

Who Are The Major Players In The Asthma Drugs Market?
Major companies operating in the asthma drugs market are Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Boehringer Ingelheim International GmbH, Novartis International AG, GlaxoSmithKline PLC, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals, Sun Pharmaceutical Industries Limited, Lupin Limited, Mundipharma International Limited, Alembic Pharmaceuticals Limited, Amphastar Pharmaceuticals Inc., Hetero Drugs Limited, Beximco Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Innoviva Inc., Pulmatrix Inc.

How Concentrated Is The Asthma Drugs Market?
•The market is highly concentrated, with the top 10 players accounting for 99% of total market revenue in 2024. This level of concentration reflects strong patent protection, high regulatory approval requirements, significant R&D investments, complex biologics development, and stringent quality and safety standards associated with respiratory therapeutics. Leading players such as Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Boehringer Ingelheim International GmbH, Novartis International AG, GlaxoSmithKline PLC, Chiesi Farmaceutici S.p.A., Cipla Limited, Teva Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals hold substantial market shares through extensive product portfolios, strong global distribution networks, advanced inhalation technologies, and continuous innovation in combination therapies and biologics. As the prevalence of asthma continues to rise globally, increasing demand for targeted therapies, biologics, and patient-friendly drug delivery systems is expected to further strengthen the competitive positioning of these leading companies in the market.

•Leading companies include:
oSanofi S.A. (57%)
oAstraZeneca PLC (14%)
oRoche Holding AG (11%)
oBoehringer Ingelheim International GmbH (5%)
oNovartis International AG (4%)
oGlaxoSmithKline PLC (4%)
oChiesi Farmaceutici S.p.A. (2%)
oCipla Limited (1%)
oTeva Pharmaceutical Industries Ltd. (1%)
oHikma Pharmaceuticals (0.4%)

Request A Free Sample Of The Asthma Drugs Market Report
https://www.thebusinessresearchcompany.com/sample_request?id=11924&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Who Are The Key Raw Material Suppliers In The Asthma Drugs Market?
•Major raw material suppliers in the asthma drugs market include Lonza Group, BASF, Evonik Industries, Cambrex, Siegfried Holding, Divis Laboratories, Laurus Labs, Aurobindo Pharma, Teva Active Pharmaceutical Ingredients, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Piramal Pharma Solutions, Dishman Carbogen Amcis, Hikal, Granules India, Alkem Laboratories, Ipca Laboratories, Zhejiang NHU, Shandong Xinhua Pharmaceutical, Wuxi AppTec, Porton Pharma Solutions, Catalent, Recipharm, Sterling Pharma Solutions, and Seqens.

Who Are The Leading Wholesalers Or Distributors In The Asthma Drugs Market?
•Major wholesalers or distributors in the asthma drugs market include McKesson, Cencora, Cardinal Health, Walgreens Boots Alliance, CVS Health, Phoenix Group, Alliance Healthcare, Zuellig Pharma, Sinopharm Group, Shanghai Pharmaceuticals, Medipal Holdings, Suzuken, Itochu Corporation, Morris and Dickson, Anda, HD Smith, FFF Enterprises, Dakota Drug, Value Drug Company, Rochester Drug Cooperative, AAH Pharmaceuticals, Imperial Distributors, Smith Drug Company, and Disa Vascular.

Who Are The Major End Users Of The Asthma Drugs Market?
•Major end users in the Asthma Drugs market include Walgreens Pharmacy, CVS Pharmacy, Rite Aid, Boots, Guardian Pharmacy, Watsons Health, PharmEasy, Tata 1mg, Netmeds, and MedPlus Health Services.

What Are The Major Competitive Trends In The Market?
•Launching interchangeable biosimilar biologics is transforming the asthma drugs market by expanding access to high-cost therapies, reducing treatment expenses, and enabling wider adoption of advanced biologic treatments.
•Example: In December 2025, Celltrion announced that OMLYCLO (omalizumab-igec) received U.S. FDA approval as the first interchangeable biosimilar to XOLAIR for moderate-to-severe persistent asthma and related allergic conditions.
•Its cost-effective biosimilar approach, pharmacy-level substitution capability, and flexible dosing formats enhance affordability, improve patient access, and support broader utilization of biologic therapies while maintaining clinical efficacy and safety standards.

Which Strategies Are Companies Adopting To Stay Ahead?
•Advancing Ultra-Long-Acting Biologic Therapies To Improve Adherence And Extend Dosing Intervals In Severe Asthma Treatment
•Expanding Direct-To-Consumer Pricing Programs To Improve Affordability And Sustain Prescription Volumes
•Innovating Anti-Inflammatory Rescue Inhalers To Enhance Symptom Control And Reduce Severe Exacerbations
•Strengthening Market Competition Through Launch Of Affordable Generic Combination Inhalers

Access The Detailed Asthma Drugs Market Report Here
https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.